Post-approval studies (Phase 4)Looking for participantsNCT07581808
What this trial is testing
Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention
Who this might be right for
HypercholesterolemiaAtherosclerotic Cardiovascular Disease (ASCVD)
University Medical Centre Ljubljana 60